Pharmacodynamics of Sarafloxacin against Experimentally Induced Streptococcosis suum and Colobacillosis in Pigs

The pharmacodynamics of sarafloxacin and ciprofloxacin against experimentally induced streptococcosis and sarafloxacin, enrofloxacin against artificially induced colibacillosis in pigs were studied to provide the basis for their clinical use. Minimal inhibitory concentrations (MICs) of above three drugs were determined for Streptococcus equisilis or Escherichia coli by two fold dilution method in vitro. Then, the therapeutic trials of sarafloxacin (2.5, 5 and 10 mg/kg) and ciprofloxacin (5 mg/kg) against experimentally induced streptococcosis suum were carried out in pigs following intramuscular administration for 5 days (twice daily). The therapeutic trials of sarafloxacin (2.5, 5 and 10 mg/kg) and enrofloxacin (5 mg/kg) against artificially induced colibacillosis were performed in pigs following intramuscular administration for 3 successive days (twice daily). MICs of sarafloxacin and ciprofloxacin were 0.8 and 0.8 mg/L for S.equisimilis, respectively. MICs of sarafloxacin and enrofloxacin were 0.05 and 0.05 mg/L for E.coli, respectively. Following the treatment with sarafloxacin (2.5, 5 and 10 mg/kg) and ciprofloxacin (5 mg/kg) against Streptococcosis suum for 5 days, the curative rates of the infected pigs were 60%, 80%, 90% and 60%, respectively. The mortality of the infected and untreated group was 40%. Following the treatment with sarafloxacin (2.5, 5 and 10 mg/kg) and enroloxacin (2.5 mg/kg) against colobacillosis for 3 days, the curative rates of the infected pigs were 80%, 90%, 90% and 90%, respectively. The mortality of the infected and untreated group was 30%.